Compare
Outset Medical, Inc. vs Vaso Corp vs Ceribell, Inc. vs Axogen, Inc.
| Latest fiscal year | Outset Medical, Inc. OM | Vaso Corp VASO | Ceribell, Inc. CBLL | Axogen, Inc. AXGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $119.48M | $89.10M | $89.06M | $225.21M |
| Revenue growth (YoY) | +5.1% | +2.7% | +36.1% | +20.2% |
| Gross margin | 39.1% | 61.4% | 87.9% | 74.3% |
| Operating margin | -55.8% | -3.2% | -65.6% | -3.5% |
| Net margin | -68.3% | 1.8% | -60.0% | -7.0% |
| Net income | -$81.65M | $1.57M | -$53.41M | -$15.70M |
| EPS (Diluted) | -$5.37 | $0.01 | -$1.46 | -$0.34 |
| Operating cash flow | -$46.33M | $9.27M | -$40.81M | $812.0K |
| Free cash flow | -$47.12M | n/a | -$41.58M | -$2.93M |
| Cash & equivalents | $35.01M | $35.05M | $40.48M | $35.55M |
| Total assets | $264.50M | $88.35M | $195.80M | $221.69M |
| Total liabilities | $137.54M | n/a | $40.47M | $92.84M |
| Shareholders' equity | $126.95M | $29.43M | $155.34M | $128.85M |
| Return on year-end equity | -64.3% | 5.3% | -34.4% | -12.2% |
| Shares outstanding | 18.17M | 175.95M | 37.49M | 47.20M |
Revenue, most recent five fiscal years
| Fiscal year | Outset Medical, Inc. | Vaso Corp | Ceribell, Inc. | Axogen, Inc. |
|---|---|---|---|---|
| Latest | $119.48M Ended 2025-12-31 | $89.10M Ended 2025-12-31 | $89.06M Ended 2025-12-31 | $225.21M Ended 2025-12-31 |
| 1 year earlier | $113.69M Ended 2024-12-31 | $86.77M Ended 2024-12-31 | $65.44M Ended 2024-12-31 | $187.34M Ended 2024-12-31 |
| 2 years earlier | $130.38M Ended 2023-12-31 | $81.02M Ended 2023-12-31 | $45.23M Ended 2023-12-31 | $159.01M Ended 2023-12-31 |
| 3 years earlier | $115.38M Ended 2022-12-31 | $79.29M Ended 2022-12-31 | n/a | $138.58M Ended 2022-12-31 |
| 4 years earlier | $102.60M Ended 2021-12-31 | $75.58M Ended 2021-12-31 | n/a | $127.36M Ended 2021-12-31 |